825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Reports First Quarter 2026 Financial Results and Provides Business Update
Annual Report to Security Holders
Vaxcyte Enters $500 Million Sales Agreement with Leerink Partners
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vaxcyte Enters Underwriting Agreement for $550 Million Stock Offering
Vaxcyte, Inc. Amends Executive Change in Control Agreements
Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
Material Contracts
FY 2024
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Submission Upload
Correspondence